BioSpace News Archive

As Eisai Inc. continues to bring innovative medicines and dynamic solutions to the marketplace, the company announces today the expansion of its leadership team to include two key appointments in the areas of Corporate Affairs and Market Access.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it received notice from The Nasdaq Stock Market LLC (“NASDAQ”) on January 31, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule

Organizations Launch Social Media Campaign and Offer SightMatters.com to Provide People with AMD and Caregivers with Educational Information, AMD Action Plan and More

License agreement to utilise Affimer proteins in next generation cell and gene therapies

BiomX Inc. announced that the Tel Aviv Stock Exchange has approved the listing of its common shares, with trading effective February 6th, 2020.

United Therapeutics Corporation announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer.

Stock option award offered as inducement to Ivor Macleod, new Chief Financial Officer of Athersys

iVeena Delivery Systems, Inc., a clinical stage biopharmaceutical company with developmental products in cornea and cataract, announces the appointment of Dr. Amir Shojaei to the iVeena Board of Directors.

Currently there are no therapies or vaccines for patients infected with 2019-nCoV coronavirus around the world.

Centene Corporation announced the appointment of Chris Koster to Senior Vice President, Secretary and General Counsel, effective February 19, 2020.